Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium
Abstract:INTRODUCTION:
Gemtuzumab ozogamicin (GO, MylotargTM) was re-approved by the FDA and has been commercially available since September 2017. Prior to re-approval, adults and children with relapsed/refractory AML or APL were treated with GO obtained through an expanded access program under an institutional IND at our Cancer Consortium: Fred Hutchinson Cancer Research Center (FHCRC), the University of Washington Medical Center (UWMC), Seattle Children's Hospital (SCH), and the Seattle Cancer Care All… Show more
“…New and repurposed drugs considered in this setting include GO and bortezomib. 42,43 Case: Patient was under 3 monthly follow-up. During her second follow-up, she revealed her pregnancy and the desire to continue the same despite all explanations regarding the teratogenic effects of ATRA and ATO.…”
Section: Strategies For Management Of Molecular and Hematological Relapsementioning
“…New and repurposed drugs considered in this setting include GO and bortezomib. 42,43 Case: Patient was under 3 monthly follow-up. During her second follow-up, she revealed her pregnancy and the desire to continue the same despite all explanations regarding the teratogenic effects of ATRA and ATO.…”
Section: Strategies For Management Of Molecular and Hematological Relapsementioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.